OBR Daily Commentary

forumImage

CytRx Announces Safe Administration of High Doses of Doxorubicin with Its Tumor-Targeted Drug, INNO-206

(TheStreet) July 6, 2011 - CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its tumor-targeted doxorubicin conjugate, INNO-206, is delivering doxorubicin safely at doses over 4 times higher than the standard doxorubicin dose in the Company's open-label Phase 1b safety and dose escalation clinical trial.

Read Article arrow

Winston Wong, PharmD (Posted: July 06, 2011)

quotesThis sounds like a technological breakthrough similar to what Abraxane did for Taxol. Since the dose limitation of the medication is due to clinical toxicity, as opposed to a vehicle sensitivity, use of this preparation should be more clinically accepted and signficantly improve outcomes. Let's hope that the manufacturer does not go crazy creating their "premium" price.quotes

Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...